Thèmes de recherche

Thèmes de recherche / expertise

Pour mieux déterminer l'importance chez l'homme et mieux comprendre comment ces systèmes se comportent à l'interface micro-nano-biologique, nous proposons maintenant de nous concentrer sur deux principales approches loco-régionales.

La première approche porte sur le développement d'une nouvelle radiothérapie interne nanovectorisée associée à une radiosensibilisation in situ. Le choix des radiopharmaceutiques associé au mode de délivrance et de confinement ou de ciblage intra-tumoral sera spécifiquement abordé. L'approche prend en compte nos nouvelles données originales portant sur le ciblage nanoparticulaire de la machinerie microARN impliquée dans la radiorésistance. Les jalons de cette approche incluent l'automatisation des méthodes de formulation radiopharmaceutique ainsi que l'évaluation de la dosimétrie corrélée aux réponses biologiques.

La deuxième approche porte sur l'implantation de « dépôts » biointeractifs capables d'interférer avec le comportement des cellules tumorales (en termes de migration, de différenciation et de sensibilité aux signaux d'élimination) au sein des tumeurs ou de leurs cavités de résection (chirurgie périopératoire). Cette stratégie repose en grande partie sur notre expertise dans le développement de formulations innovantes permettant de libérer des molécules bioactives (par exemple, des protéines). L'objectif de ce projet est de cibler les cellules à éliminer et de modifier leur environnement afin de les attirer et de les confiner dans une zone contrôlée pour leur destruction.

Nous prévoyons de surmonter les principales barrières technologiques limitant le « tissue homing » et le ciblage cellulaire et subcellulaire des vecteurs biomimétiques. Nous proposons de nouvelles stratégies pour le ciblage et l'élimination des cellules radiorésistantes. Notre travail vise à développer des stratégies de micro-nanomédecine mini-invasives pertinentes et optimisées pour le traitement des gliomes, ainsi que d'autres tumeurs solides, en employant des approches fondamentales et technologiques originales et nouvelles.

Publications

Sélection sur ces sept dernières années

2023

• R Molina-Peña, NH Ferreira, C Roy, L Roncali, M Najberg, S Avril, M Zarur, W Bourgeois, A Ferreirós, C Lucchi, F Cavallieri, F Hindré, G Tosi, G Biagini, F Valzania, F Berger, M Abal, A Rousseau, F Boury, C Alvarez-Lorenzo, E Garcion. (2023). Implantable SDF-1α-Loaded Silk Fibroin Hyaluronic Acid Aerogel Sponges as an Instructive Component of the Glioblastoma Ecosystem: Between Chemoattraction and Tumor Shaping into Resection Cavities. Acta Biomater. 173, 261–282.
• I Ottonelli, A Bighinati, E Adani, F Loll, R Caraffi, MA Vandelli, F Boury, G Tosi, JT Duskey, V Marigo, B Ruozi. (2023). Optimization of an Injectable Hydrogel Depot System for the Controlled Release of Retinal-Targeted Hybrid Nanoparticles. Pharmaceutics. 15 (1), 25.
• A Bikfalvi, CA da Costa, T Avril, JV Barnier, L Bauchet, L Brisson, PF Cartron, H Castel, E Chevet, H Chneiweiss, A Clavreul, B Constantin, V Coronas, T Daubon, M Dontenwill, F Ducray, N Entz-Werlé, D Figarella-Branger, I Fournier, JS Frenel, M Gabut, T Galli, J Gavard, G Huberfeld, JP Hugnot, A Idbaih, MP Junier, T Mathivet, P Menei, D Meyronet, C Mirjolet, F Morin, J Mosser, ECJ Moyal, V Rousseau, M Salzet, M Sanson, G Seano, E Tabouret, A Tchoghandjian, L Turchi, FM Vallette, S Vats, M Verreault, T Virolle. (2023). Challenges in Glioblastoma Research: Focus on the Tumor Microenvironment. Trends Cancer. 9 (1), 9–27. 

2022

• C Roy, S Avril, C Legendre, B Lelièvre, H Vellenriter, S Boni, Jérôme C, C Guillet, Y Guilloux, M Chérel, F Hindré, E Garcion. (2022). A role for Ceruloplasmin in the control of human glioblastoma cell responses to radiation. BMC Cancer. 2;22(1):843.
• Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. (2022). Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 41(5):613-621.
• Sourty B, Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Basset L, Figarella-Branger D, Morel A, Sanson M, Procaccio V, Rousseau A. (2022). Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma. Neurooncol Adv. 4(1):vdab191.
• Chuzeville, L; Boury, F; Duday, D; Moretto, E; Anand, R; Thomann, JS, (2022). Eco-friendly processes for the synthesis of amorphous calcium carbonate nanoparticles in ethanol and their stabilisation in aqueous media. Green Chem., 24, 1270-1284

2021

• R Molina-Peña, M Haji Mansor, M Najberg, JM Thomassin, B Gueza, C Alvarez-Lorenzo, E Garcion, C Jérôme, F Boury. (2021). Nanoparticle-containing electrospun nanofibrous scaffolds for sustained release of SDF-1α. International Journal of Pharmaceutics, 610 121205.
• V Simion, C Loussouarn, Y Laurent, L Roncali, D Gosset, F Reverchon, A Rousseau, F Martin, P Midoux, C Pichon, E Garcion*, P Baril*. (2021). LentiRILES, a miRNA-ON Sensor System for Monitoring the Functionality of miRNA in Cancer Biology and Therapy. RNABiology, 8, NO. S1: 198–214. *Equivalent contributions.
• D Séhédic, L Roncali, N Buchtova, S Avril, A Djoudi, M Chérel, F Boury, F Lacoeuille, F Hindré, E Garcion. (2021). Rapamycin-loaded lipid nanocapsules induce selective inhibition of the mTORC1-signaling pathway in glioblastoma cells. Frontiers in Bioengineering and Biotechnology Nanobiotechnology, 8: 602998.
• Ah-Pine, F., Casas, D., Menei, P., Boisselier, B., Garcion, E., and Rousseau, A. (2021). RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties. Translationnal Oncology 4 :100884.
• M Haji Mansor, E Garcion, B Ramalapa, N Buchtova, C Toullec, M Aucamp, J Le Bideau, F Hindré, A Dube, C Alvarez-Lorenzo, M Galleni, C Jérôme, F Boury. (2021). Polymer-based protein delivery systems for loco-regional administration. Book Chapter11, Green Synthesis in Nanomedicine and Human Health, By Richard Glover, CRC Press Taylor & Francis group, pp.249-270.

2020

• Najberg, M., Haji Mansor, M., Taillé, T., Bouré, C., Molina-Peña, R., Boury, F., Cenis, J.L., Garcion, E. *, and Alvarez-Lorenzo, C.* (2020). Aerogel sponges of silk fibroin, hyaluronic acid and heparin for soft tissue engineering: Composition-properties relationship. Carbohydrate Polymers 237, 116107. *Equivalent contributions.
• Clavreul, A., Menei, P. (2020). Mesenchymal Stromal-Like Cells in the Glioma Microenvironment: What Are These Cells? Cancers (Basel) 12(9):2628.
• Oddone, N., Boury, F., Garcion, E., Grabrucker, A.M., Martinez, M.C., Da Ros, F., Janaszewska, A., Forni, F., Vandelli, M.A., Tosi, G., Forni, F., Ruozi, B. Duskey, J. T. (2020). Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Front Pharmacol 11, 574.
• Simion, V., Henriet, E., Juric, V., Aquino, R., Loussouarn, C., Laurent, Y., Martin, F., Midoux, P., Garcion, E., Pichon, C., and Baril, P. (2020). Intracellular trafficking and functional monitoring of miRNA delivery in glioblastoma using lipopolyplexes and the miRNA-ON RILES reporter system. J Control Release 327, 429-443.
• Grégoire, H., Roncali, L., Rousseau, A., Chérel, M., Delneste, Y., Jeannin, P., Hindré, F., and Garcion, E. (2020). Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma. Front Pharmacol 11, 368.
• Ugur, D., Sottile, V., Montero-Menei, C.N., Boury, F., Zelzer, M. (2020). Relating polymeric microparticle formulation to prevalence or distribution of fibronectin and poly-d-lysine to support mesenchymal stem cell growth. Biointerphases 15, 041008.

2019

• Bailly, C., Vidal, A., Bonnemaire, C., Kraeber-Bodere, F., Chérel, M., Pallardy, A., Rousseau, C., Garcion, E., Lacoeuille, F., Hindré, F., Valable, S., Bernaudin, M., Bodet-Milin, C., Bourgeois, M. (2019). Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. Front Pharmacol 10, 772.
• Autier, L., Clavreul, A., Cacicedo, M.L., Franconi, F., Sindji, L., Rousseau, A., Perrot, R., Montero-Menei, C.N., Castro, G.R., Menei, P. (2019). A new glioblastoma cell trap for implantation after surgical resection. Acta Biomater 84, 268-279.
• Lajous, H., Lelievre, B., Vauleon, E., Lecomte, P., Garcion, E. (2019). Rethinking Alkylating(-Like) Agents for Solid Tumor Management. Trends Pharmacol Sci 40, 342-357.
• Clavreul, A., Pourbaghi-Masouleh, M., Roger, E., Menei, P. (2019). Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far. Int J Nanomedicine 14, 2497-2513.
• Clavreul, A., Soulard, G., Lemée, J.M., Rigot, M., Fabbro-Peray, P., Bauchet, L., Figarella-Branger, D., Menei, P., and network, F.G.B. (2019). The French glioblastoma biobank (FGB): a national clinicobiological database. Journal of translational medicine 17, 133.
• Dardaud, L.M., Bris, C., Desquiret-Dumas, V., Boisselier, B., Tabouret, E., Mokhtari, K., Figarella-Branger, D., Rousseau, A.*, Procaccio, V.* (2019). High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma. Neuro Oncol. 21(8): 1084–1085. *Equivalent contributions.
• Lepareur, N., Lacoeuille, F., Bouvry, C., Hindré, F., Garcion, E., Chérel, M., Noiret, N., Garin, E., Knapp, F.F.R., Jr. (2019). Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Frontiers in medicine 6, 132.
• Najberg, M., Haji Mansor, M., Boury, F., Alvarez-Lorenzo, C., Garcion, E. (2019). Reversing the Tumor Target: Establishment of a Tumor Trap. Front Pharmacol 10, 887.
• André, E.M., Delcroix, G.J., Kandalam, S., Sindji, L., and Montero-Menei, C.N. (2019). A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells. Pharmaceutics 11: 526.
• Ah-Pine, A Rousseau. Les tumeurs du système nerveux central. Encyclopédie Médico-Chirurgicale, Elsevier Masson, (2019).

2018

• Haji Mansor, M., Najberg, M., Contini, A., Alvarez-Lorenzo, C., Garcion, E., Jerome, C., Boury, F. (2018). Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1alpha into PLGA/PEG-PLGA nanoparticles to achieve sustained release. Eur J Pharm Biopharm 125, 38-50.
• Boisselier, B., Dugay, F., Belaud-Rotureau, M.A., Coutolleau, A., Garcion, E., Menei, P., Guardiola, P., Rousseau, A. (2018). Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma. Oncotarget 9, 36017-36028.
• Anthiya, S., Griveau, A., Loussouarn, C., Baril, P., Garnett, M., Issartel, J.P., Garcion, E. (2018). MicroRNA-Based Drugs for Brain Tumors. Trends in Cancer 4, 222-238.
• Lajous, H., Riva, R., Lelievre, B., Tétaud, C., Avril, S., Hindré, F., Boury, F., Jérome, C., Lecomte, P., Garcion, E. (2018). Hybrid Gd(3+)/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. Biomaterials Science 6, 2386-2409.
• Clavreul, A., Roger, E., Pourbaghi-Masouleh, M., Lemaire, L., Tétaud, C., Menei, P. (2018). Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug delivery 25, 1756-1765.
• Dreyfus, M., EL-ATIFI, M., Court, M., Bidart, M., Coutton, C., Leclech, C., Ballester, B., Garcion, E., Bouamrani, A., Berger, F., R., Wion, D. (2018). Reprogramming glioma cell cultures with retinoic acid: Additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy. Glioma 1, 66-78.
• Lemée, J.M., Clavreul, A., Aubry, M., Com, E., de Tayrac, M., Mosser, J., Menei, P. (2018). Integration of transcriptome and proteome profiles in glioblastoma: looking for the missing link. BMC molecular biology 19, 13.

2017

• Kandalam, S., Sindji, L., Delcroix, G.J., Violet, F., Garric, X., Andre, E.M., Schiller, P.C., Venier-Julienne, M.C., des Rieux, A., Guicheux, J., Montero-Menei, C. N. (2017). Pharmacologically active microcarriers delivering BDNF within a hydrogel: Novel strategy for human bone marrow-derived stem cells neural/neuronal differentiation guidance and therapeutic secretome enhancement. Acta Biomater 49, 167-180.
• Ramalapa, B., Crasson, O., Vandevenne, M., Gibaud, A., Garcion, E., Cordonnier, T., Galleni, M., Boury, F. (2017). Protein-polysaccharide complexes for enhanced protein delivery in hyaluronic acid templated calcium carbonate microparticles. J Mat Chem B 5, 7360-7368.
• Sehedic, D., Chourpa, I., Tétaud, C., Griveau, A., Loussouarn, C., Avril, S., Legendre, C., Lepareur, N., Wion, D., Hindré, F., Davodeau, F., Garcion, E. (2017). Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma. Theranostics 7, 4517-4536
• Boisselier, B., De Carli, E., Rousseau, A. (2017). Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma. J Neurooncol 133, 217-219.
• Cikankowitz, A., Clavreul, A., Tetaud, C., Lemaire, L., Rousseau, A., Lepareur, N., Dabli, D., Bouchet, F., Garcion, E., Menei, P., Couturier, O., Hindré, F. (2017). Characterization of the distribution, retention, and efficacy of internal radiation of (188)Re-lipid nanocapsules in an immunocompromised human glioblastoma model. J Neurooncol 131, 49-58.
• Clavreul, A., Pourbaghi-Masouleh, M., Roger, E., Lautram, N., Montero-Menei, C.N., Menei, P. (2017). Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? J Exp Clin Cancer Res 36, 135.
• El Ayoubi, R., Boisselier, B., Rousseau, A. (2017). Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases. J Neurooncol 134, 465-467.

Contacts

Adresse postale

CRCI2NA - UMR Inserm 1307 CNRS 6075
équipe 5 GLIAD
Institut de Biologie en Santé PBH-IRIS
CHU Angers
4, Rue Larrey
49933 Angers Cedex

Responsable(s)

emmanuel.garcion @ univ-angers.fr (emmanuel.garcion @ univ-angers.fr)

Contacts

+33 (0) 2 44 68 85 43